Cargando…
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, trea...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302344/ https://www.ncbi.nlm.nih.gov/pubmed/28034355 http://dx.doi.org/10.2174/1381612822666161230142931 |
_version_ | 1783381958831636480 |
---|---|
author | Li, Bin Li, Weihong Li, Xiaoli Zhou, Hong |
author_facet | Li, Bin Li, Weihong Li, Xiaoli Zhou, Hong |
author_sort | Li, Bin |
collection | PubMed |
description | Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease. |
format | Online Article Text |
id | pubmed-6302344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-63023442019-01-14 Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis Li, Bin Li, Weihong Li, Xiaoli Zhou, Hong Curr Pharm Des Article Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease. Bentham Science Publishers 2017-03 2017-03 /pmc/articles/PMC6302344/ /pubmed/28034355 http://dx.doi.org/10.2174/1381612822666161230142931 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Li, Bin Li, Weihong Li, Xiaoli Zhou, Hong Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis |
title | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis |
title_full | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis |
title_fullStr | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis |
title_full_unstemmed | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis |
title_short | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis |
title_sort | inflammation: a novel therapeutic target/direction in atherosclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302344/ https://www.ncbi.nlm.nih.gov/pubmed/28034355 http://dx.doi.org/10.2174/1381612822666161230142931 |
work_keys_str_mv | AT libin inflammationanoveltherapeutictargetdirectioninatherosclerosis AT liweihong inflammationanoveltherapeutictargetdirectioninatherosclerosis AT lixiaoli inflammationanoveltherapeutictargetdirectioninatherosclerosis AT zhouhong inflammationanoveltherapeutictargetdirectioninatherosclerosis |